CN104643073A - 一种用于调理脂肪代谢障碍人群的亚健康状态的组合物 - Google Patents
一种用于调理脂肪代谢障碍人群的亚健康状态的组合物 Download PDFInfo
- Publication number
- CN104643073A CN104643073A CN201510069103.8A CN201510069103A CN104643073A CN 104643073 A CN104643073 A CN 104643073A CN 201510069103 A CN201510069103 A CN 201510069103A CN 104643073 A CN104643073 A CN 104643073A
- Authority
- CN
- China
- Prior art keywords
- phase
- composition
- fat
- kilograms
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 206010049287 Lipodystrophy acquired Diseases 0.000 title claims abstract description 15
- 208000006132 lipodystrophy Diseases 0.000 title claims abstract description 15
- 230000001105 regulatory effect Effects 0.000 title abstract description 9
- 239000012071 phase Substances 0.000 claims description 61
- 239000000463 material Substances 0.000 claims description 31
- 230000036541 health Effects 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- 230000000474 nursing effect Effects 0.000 claims description 13
- 239000008346 aqueous phase Substances 0.000 claims description 12
- 238000004945 emulsification Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 4
- 239000004519 grease Substances 0.000 claims description 4
- 238000009413 insulation Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 51
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 22
- 230000004060 metabolic process Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 238000003786 synthesis reaction Methods 0.000 abstract description 12
- 230000001603 reducing effect Effects 0.000 abstract description 11
- 210000000577 adipose tissue Anatomy 0.000 abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 7
- 230000002267 hypothalamic effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 102000004882 Lipase Human genes 0.000 abstract description 6
- 108090001060 Lipase Proteins 0.000 abstract description 6
- 239000004367 Lipase Substances 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 230000014509 gene expression Effects 0.000 abstract description 6
- 235000019421 lipase Nutrition 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000029142 excretion Effects 0.000 abstract description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 abstract description 4
- 235000011187 glycerol Nutrition 0.000 abstract description 4
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000007493 shaping process Methods 0.000 abstract description 3
- 230000037149 energy metabolism Effects 0.000 abstract description 2
- 229940074391 gallic acid Drugs 0.000 abstract description 2
- 235000004515 gallic acid Nutrition 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- 230000010189 intracellular transport Effects 0.000 abstract description 2
- 239000002207 metabolite Substances 0.000 abstract description 2
- 150000003431 steroids Chemical class 0.000 abstract description 2
- PLSDWRYNZIVQKX-BGKYVOMCSA-N (3S)-3-amino-4-[[(2S)-1-[[2-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-3-methylsulfanylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CNC=N4)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)N PLSDWRYNZIVQKX-BGKYVOMCSA-N 0.000 abstract 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 abstract 1
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 102000049953 human LEP Human genes 0.000 abstract 1
- 230000010627 oxidative phosphorylation Effects 0.000 abstract 1
- 108010073085 tachykinin neuropeptide gamma Proteins 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 description 57
- 108010092277 Leptin Proteins 0.000 description 57
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 57
- 229940039781 leptin Drugs 0.000 description 57
- 239000003925 fat Substances 0.000 description 39
- 210000003491 skin Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 240000007154 Coffea arabica Species 0.000 description 11
- 235000007460 Coffea arabica Nutrition 0.000 description 11
- 240000002853 Nelumbo nucifera Species 0.000 description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 244000042664 Matricaria chamomilla Species 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 10
- 235000006886 Zingiber officinale Nutrition 0.000 description 10
- 210000001015 abdomen Anatomy 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 235000008397 ginger Nutrition 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000001217 buttock Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 210000004247 hand Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 6
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
- 241000219357 Cactaceae Species 0.000 description 6
- 244000169962 Dioscorea macrostachya Species 0.000 description 6
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 240000001155 Opuntia dillenii Species 0.000 description 6
- 235000006544 Opuntia dillenii Nutrition 0.000 description 6
- 241000206572 Rhodophyta Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 244000299461 Theobroma cacao Species 0.000 description 6
- 244000273928 Zingiber officinale Species 0.000 description 6
- 229960004203 carnitine Drugs 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 210000002414 leg Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 241001133760 Acoelorraphe Species 0.000 description 5
- 241000522254 Cassia Species 0.000 description 5
- 241000167550 Centella Species 0.000 description 5
- 244000146462 Centella asiatica Species 0.000 description 5
- 235000004032 Centella asiatica Nutrition 0.000 description 5
- 244000037364 Cinnamomum aromaticum Species 0.000 description 5
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 5
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 5
- 235000004429 Matricaria chamomilla var recutita Nutrition 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 240000003444 Paullinia cupana Species 0.000 description 5
- 235000000556 Paullinia cupana Nutrition 0.000 description 5
- 206010040925 Skin striae Diseases 0.000 description 5
- 235000009470 Theobroma cacao Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000001841 zingiber officinale Substances 0.000 description 5
- 241000234314 Zingiber Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 102000005861 leptin receptors Human genes 0.000 description 4
- 108010019813 leptin receptors Proteins 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 3
- 208000035484 Cellulite Diseases 0.000 description 3
- 235000007716 Citrus aurantium Nutrition 0.000 description 3
- 240000003791 Citrus myrtifolia Species 0.000 description 3
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 3
- 235000016646 Citrus taiwanica Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 102400000064 Neuropeptide Y Human genes 0.000 description 3
- 206010049752 Peau d'orange Diseases 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000036232 cellulite Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 229940100554 isononyl isononanoate Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229940097411 palm acid Drugs 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000001453 quaternary ammonium group Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229920005573 silicon-containing polymer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- -1 stearoyl inulin Chemical compound 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 208000023184 Body fat disease Diseases 0.000 description 2
- 241000905957 Channa melasoma Species 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000031439 Striae Distensae Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 108010064926 acyl-CoA carboxylase Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 206010057361 Blood brain barrier defect Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101800003845 Neuropeptide Y Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 239000006160 differential media Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组分 | 脂肪酸合成酶活性抑制 | 脂肪细胞分化的抑制 |
本产品的乙醇溶解物 | 强抑制作用 | 强抑制作用 |
乙醇 | 无 | 无 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510069103.8A CN104643073B (zh) | 2015-02-10 | 2015-02-10 | 一种用于调理脂肪代谢障碍人群的亚健康状态的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510069103.8A CN104643073B (zh) | 2015-02-10 | 2015-02-10 | 一种用于调理脂肪代谢障碍人群的亚健康状态的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104643073A true CN104643073A (zh) | 2015-05-27 |
CN104643073B CN104643073B (zh) | 2016-11-30 |
Family
ID=53235122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510069103.8A Active CN104643073B (zh) | 2015-02-10 | 2015-02-10 | 一种用于调理脂肪代谢障碍人群的亚健康状态的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104643073B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105194642A (zh) * | 2015-10-09 | 2015-12-30 | 深圳市容大生物技术有限公司 | 一种疏通乳房微循环养护自体腺胞的组合物及制备方法 |
CN105997635A (zh) * | 2016-06-02 | 2016-10-12 | 梁婷 | 一种气血减肥霜及其制备方法 |
CN108324929A (zh) * | 2018-03-09 | 2018-07-27 | 深圳市容大生物技术有限公司 | 一种减少体脂率及体脂反弹的组合物及其制备方法和应用 |
CN108477453A (zh) * | 2018-05-02 | 2018-09-04 | 东莞市合纵食品有限公司 | 一种大麦若叶组合物及其饮料 |
CN108991315A (zh) * | 2018-07-12 | 2018-12-14 | 东莞市合纵食品有限公司 | 一种大麦若叶饮料的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003202335A (ja) * | 2002-01-07 | 2003-07-18 | Toshiharu Mori | 化粧料の成分選択方法及び化粧料 |
CN103237555A (zh) * | 2010-02-19 | 2013-08-07 | 玫琳凯有限公司 | 外用皮肤护理制剂 |
CN103284913A (zh) * | 2013-05-31 | 2013-09-11 | 吴克 | 一种溶脂精油 |
CN103315934A (zh) * | 2013-06-21 | 2013-09-25 | 深圳市金因生物技术有限公司 | 促进皮肤水通道蛋白开启的组合物及其制备方法 |
CN103462881A (zh) * | 2013-10-10 | 2013-12-25 | 深圳市金因生物技术有限公司 | 一种可促进皮肤微生态平衡的组合物及其制备方法 |
-
2015
- 2015-02-10 CN CN201510069103.8A patent/CN104643073B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003202335A (ja) * | 2002-01-07 | 2003-07-18 | Toshiharu Mori | 化粧料の成分選択方法及び化粧料 |
CN103237555A (zh) * | 2010-02-19 | 2013-08-07 | 玫琳凯有限公司 | 外用皮肤护理制剂 |
CN103284913A (zh) * | 2013-05-31 | 2013-09-11 | 吴克 | 一种溶脂精油 |
CN103315934A (zh) * | 2013-06-21 | 2013-09-25 | 深圳市金因生物技术有限公司 | 促进皮肤水通道蛋白开启的组合物及其制备方法 |
CN103462881A (zh) * | 2013-10-10 | 2013-12-25 | 深圳市金因生物技术有限公司 | 一种可促进皮肤微生态平衡的组合物及其制备方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105194642A (zh) * | 2015-10-09 | 2015-12-30 | 深圳市容大生物技术有限公司 | 一种疏通乳房微循环养护自体腺胞的组合物及制备方法 |
CN105194642B (zh) * | 2015-10-09 | 2018-04-17 | 深圳市容大生物技术有限公司 | 一种疏通乳房微循环养护自体腺胞的组合物及制备方法 |
CN105997635A (zh) * | 2016-06-02 | 2016-10-12 | 梁婷 | 一种气血减肥霜及其制备方法 |
CN108324929A (zh) * | 2018-03-09 | 2018-07-27 | 深圳市容大生物技术有限公司 | 一种减少体脂率及体脂反弹的组合物及其制备方法和应用 |
CN108324929B (zh) * | 2018-03-09 | 2021-07-13 | 深圳市容大生物技术有限公司 | 一种减少体脂率及体脂反弹的组合物及其制备方法和应用 |
CN108477453A (zh) * | 2018-05-02 | 2018-09-04 | 东莞市合纵食品有限公司 | 一种大麦若叶组合物及其饮料 |
CN108991315A (zh) * | 2018-07-12 | 2018-12-14 | 东莞市合纵食品有限公司 | 一种大麦若叶饮料的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104643073B (zh) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104643073B (zh) | 一种用于调理脂肪代谢障碍人群的亚健康状态的组合物 | |
CN103142759A (zh) | 一种补精益气、养血安神的口服液 | |
CN103110103A (zh) | 清脂减肥营养餐粉 | |
KR20130073579A (ko) | 천연물 복합 발효 추출물을 유효성분으로 하는 피부 및 두피 상태 개선용 조성물 | |
CN101904946B (zh) | 一种全效茶薰天然活性脂肪抑制配方 | |
CN107549554B (zh) | 具有美容祛斑功能的果汁发酵饮品及其制备方法 | |
CN101828714B (zh) | 一种用于延缓衰老的保健食品 | |
CN110583780A (zh) | 一种可以预防和降低高血压和高尿酸的固体饮料 | |
US8715650B2 (en) | Bathing composition and method for preparing same | |
CN104126744A (zh) | 黑枸杞延春美容片 | |
CN102396707A (zh) | 一种养颜瘦身营养食品配方 | |
CN101946895B (zh) | 一种以泥鳅为主料的功能食品及其制备方法 | |
CN102090453A (zh) | 瘦身美奶茶 | |
CN102008083B (zh) | 一种缓解体力疲劳、祛黄褐斑的保健食品 | |
CN106174286A (zh) | 高级金枸杞营养果酱 | |
CN108013459A (zh) | 一种具有减肥美容功能的保健食品及其制备方法 | |
CN103181557A (zh) | 具有减肥功能的营养食品及其制备方法 | |
CN105454601A (zh) | 黑青稞减肥茶(奶茶) | |
CN109363028A (zh) | 一种缓解体力疲劳的西洋参饮品制备方法 | |
CN108324929A (zh) | 一种减少体脂率及体脂反弹的组合物及其制备方法和应用 | |
CN104147173B (zh) | 一种治疗急性酒精中毒的中药组合物 | |
CN110013028A (zh) | 一种食疗养生保健产品 | |
CN102319355A (zh) | 一种治疗多动症的中药组方及其丸剂的制备方法 | |
CN107184868A (zh) | 一种能够有效降脂减肥、增强免疫力的中药组合物 | |
CN105433125A (zh) | 一种养肝药剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 518057, No. 7, No. 1, Nanshan District science and technology, Guangdong, Shenzhen Applicant after: SHENZHEN RONGDA BIOTECHNOLOGY CO., LTD. Address before: 518057, No. 7, No. 1, Nanshan District science and technology, Guangdong, Shenzhen Applicant before: Shenzhen Gene Biological Technology Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHENZHEN GENE BIOTECHNOLOGY CO., LTD. TO: SHENZHEN RONGDA BIO-TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 518000 10a, B and C, building 8, qiaochengfang, No. 4080, Qiaoxiang Road, Gaofa community, Shahe street, Nanshan District, Shenzhen, Guangdong Patentee after: Shenzhen Rongda Biotechnology Co.,Ltd. Address before: No.7, Keji Zhongyi Road, Nanshan District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN RONGDA BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address |